Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5322MR)

This product GTTS-WQ5322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13041MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12303MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ6223MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ9741MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ14051MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ1953MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ7207MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ11244MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.